HepQuant Presents at the 2017 Rocky Mountain Life Science Investor and Partnering Conference

DENVER (October 12th, 2017) — HepQuant, LLC,  a Greenwood Village, Colo.-based company with a unique, patented and patent-pending technology for evaluating the liver in patients with chronic liver disease, today announced it presented at the 2017 Rocky Mountain Life Science and Partnering Conference on October 3rd, 2017.  HepQuant was one of 30 companies chosen to present out of 72 total applications.  The Rocky Mountain Life Science Investor and Partnering Conference is the largest U.S. bioscience industry investor conference outside of the coasts.  If interested in speaking with HepQuant please see the contact information below.

About HepQuant

HepQuant products are investigational combination drug / diagnostic devices and have not yet been evaluated or approved by the US Food and Drug Administration (FDA) for commercial sale. They are currently available for investigational use via the FDA IDE application process. For additional information, please visit our website at www.hepquant.com.

INVESTOR CONTACT
Brad Everson, Chief Business Development Officer
Ph: (303) 923-2150 | E: brad.everson@hepquant.com

MEDIA CONTACT
Tom Kennedy
E: tkennedy@hepquant.com | M: (720) 507-4164